- AttorneyOne.com – Finding An Attorney Online, Just Got Easier

Oncological, nephrological healthcare professionals and patients are notified by the US FDA and Amgen that all ESAs must be used under a REMS risk management program. FDA Alert on Erythropoiesis-Stimulating Agents (ESAs) FDA requires a REMS because studies have shown that ESAs (Procrit, Epogen and Aranesp) can increase the risk of tumor growth and shorten [...]

Risk Managers and Pharmacy healthcare personnel are informed by the FDA that certain Hospira Injectable Drug Products are recalled because of visible particles embedded in the glass located at the neck of the vial which can cause adverse events. Background of Hospira Injectable Drug Products Certain injectable drug products, by Hospira, Inc, are used to [...]

The public is notified by the FDA that there is an increased risk of second primary malignancies (new types of cancer) in patients with newly-diagnosed multiple myeloma who received Revlimid. Background of Revlimid (lenalidomide) Revlimid (lenalidomide) is used for the treatment of myelodysplastic syndrome (a type of blood disorder) and along with other drugs to [...]

Medical professionals as well as patients all over the US have been alerted by the FDA on the issue of counterfeit products so labeled as Avastin (Bevacizumab). Background of Avastin (Bevacizumab) Avastin (Bevacizumab) is a medical injection that is used in the treatment of cancer, with its usage mostly being highlighted in hospitals, clinics, and [...]